MagForce

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on MagForce. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
QuickView

10.11.21

MagForce — Primed to execute on its growth strategy

Healthcare |
Update

10.11.21

MagForce — Primed to execute on its growth strategy

Healthcare |
Update

14.07.21

MagForce — Time to capitalise on growth potential

Healthcare |
Update

11.02.21

MagForce — NanoTherm on track for US approval in 2021

Visit Website

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(73.9)	(99.0)	(99.5)
Relative	(75.2)	(99.0)	(99.4)
52 week high/low	€3.6/€0.0

Financials

MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).